AFP and hepatocellular carcinoma: In the development cohort, AFP and PIVKA-II concentrations were found to be higher in patients with HCC than in healthy controls (p < 0.0010) and patients with chronic liver disease (p < 0.0010), with levels increasing with HCC stage (Fig. 1a, b; Additional file 1: Table S1).